Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients.
about
Would artificial neural networks implemented in clinical wards help nephrologists in predicting epoetin responsiveness?Costs Associated With Intravenous Darbepoetin Versus Epoetin Therapy in Hemodialysis Patients: A Randomized Controlled Trial.Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients.The management of anemia in pediatric peritoneal dialysis patients. Guidelines by an ad hoc European committee.Pharmacoeconomic considerations in the health system management of anaemia in patients with chronic kidney disease and end stage renal disease.A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis.The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients.Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United StatesReduced responsiveness to epoetin at re-exposure after prolonged epoetin-free period in anemic hemodialysis patients with end-stage renal disease.Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.Recombinant human epoetin beta in the treatment of renal anemia.Anemia Management in the China Dialysis Outcomes and Practice Patterns StudyUse of agents stimulating erythropoiesis in digestive diseasesMeeting new challenges in the management of anemia of chronic kidney disease through collaborative care with pharmacists.A review of the costs and cost effectiveness of interventions in chronic kidney disease: implications for policy.Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review.The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.Efficacy and safety of subcutaneous administration of lyophilized powder of alfa-erythropoietin to maintain hemoglobin concentrations among hemodialysis patients.Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.A model of erythropoiesis in adults with sufficient iron availability.Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.Epoetin in haemodialysis patients: impact of change from subcutaneous to intravenous routes of administration.Effect of switching from subcutaneous to intravenous administration of epoetin-alpha in haemodialysis patients: results from a Swedish multicentre survey.The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin beta in peritoneal dialysis patients with chronic renal anaemia.Prediction of hemoglobin levels in individual hemodialysis patients by means of a mathematical model of erythropoiesis.
P2860
Q33257895-DFA504B3-2905-4C93-B8A4-3AFFEE705471Q33887606-80064CC9-599F-4AEC-8E0B-8C5887AAD35BQ34997753-F9F5184A-1E75-4E86-8ED3-6A294C3C4F00Q35128983-23A51D24-A3E0-4A57-9F2F-68074B8E7308Q35207564-D352ABB2-38EA-4138-B5B6-39667A288C20Q35574041-C62D21A8-1445-4A72-A31C-363DF721B68FQ35827701-2BB3B47E-F425-461B-B97F-53315F139D24Q35985899-5D837EE6-7766-4E7D-9E02-29A984BD065DQ36123609-FA1BCC8D-F23C-44E5-A478-98ECCC51E795Q36147634-EA11ED8C-521C-4D8D-8938-F5308DCC1E5BQ36476556-86FF1343-B09D-41B7-B924-D28F3F0AA874Q36661294-2C6480EE-0816-4993-8464-619118FFCD8AQ37033628-A15F5BD3-29C9-47E6-B4B5-4EF15C2C5CB0Q37368733-77BE2233-70BA-47A7-84ED-754DDF1699AAQ37614087-3267B143-37E5-4F4F-A1D2-6077F7D4A64FQ37889260-1DBE24DD-D09B-484F-B421-779DD1249F0BQ38228519-FBBC5EFD-EE92-4D2F-B39B-0DD67F9C9A20Q38740871-8A9F4B2C-FF12-4BEB-9402-8BA62F0E33B8Q42364444-E653B854-BBB7-43DB-8FB9-BDD4581BC8A4Q47366603-0FB59449-29E9-4360-B636-19DA1DE0D5A6Q47904886-77C61B0A-0F7C-47E1-B970-A438E0E5A632Q50512562-BA77C693-6CD2-4B3A-8172-1273639E5EB6Q50743789-C09F8E8C-D4A3-4A3A-B3F6-649D313E515AQ50746752-080CEB7B-C474-4221-A8EA-09F0172B33A7Q50757332-3E4D50FD-6DBF-496A-AD1F-AA6D59A6E296Q53913005-DEA94017-B5AD-4120-B2D2-D246D924C120Q55260189-819A30E8-5EB0-46C8-9098-492C827E4A0F
P2860
Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Meta-analysis of subcutaneous ...... emia in hemodialysis patients.
@en
Meta-analysis of subcutaneous ...... emia in hemodialysis patients.
@nl
type
label
Meta-analysis of subcutaneous ...... emia in hemodialysis patients.
@en
Meta-analysis of subcutaneous ...... emia in hemodialysis patients.
@nl
prefLabel
Meta-analysis of subcutaneous ...... emia in hemodialysis patients.
@en
Meta-analysis of subcutaneous ...... emia in hemodialysis patients.
@nl
P2093
P356
P1476
Meta-analysis of subcutaneous ...... emia in hemodialysis patients.
@en
P2093
Anatole Besarab
Carolina M Reyes
John Hornberger
P304
P356
10.1053/AJKD.2002.34881
P577
2002-09-01T00:00:00Z